Monia Sisi
Bologna, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Capmatinib-Induced Liver Injury as Emerging Toxicity of MET Inhibitors in Patients With NSCLC Pretreated With Immune Checkpoint Inhibitors.
Journal: JTO clinical and research reports
Published: June 20, 2023
Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
Journal: Immunotherapy
Published: November 16, 2022
Psychiatric Adverse Reactions to Anaplastic Lymphoma Kinase Inhibitors in Non-Small-Cell Lung Cancer: Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System.
Journal: Targeted oncology
Published: December 16, 2021
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: a case report within the experience of a single institution.
Journal: Anti-cancer drugs
Published: March 04, 2021
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
Journal: Anti-cancer drugs
Published: August 23, 2020
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: rationale and clinical implication.
Journal: Future oncology (London, England)
Published: June 17, 2020
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma.
Journal: Critical reviews in oncology/hematology
Published: June 05, 2020
Showing 1-9 of 9
Last Updated: 09/26/2026